Sienna Biopharmaceuticals Inc’s (SNNA) Lock-Up Period To End on January 23rd

Sienna Biopharmaceuticals’ (NASDAQ:SNNA) lock-up period will end on Tuesday, January 23rd. Sienna Biopharmaceuticals had issued 4,333,333 shares in its public offering on July 27th. The total size of the offering was $64,999,995 based on an initial share price of $15.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.

Separately, Guggenheim initiated coverage on Sienna Biopharmaceuticals in a research report on Tuesday, December 5th. They set a “neutral” rating and a $21.00 price objective on the stock.

Shares of Sienna Biopharmaceuticals (NASDAQ:SNNA) opened at $18.06 on Tuesday. Sienna Biopharmaceuticals has a 12-month low of $15.22 and a 12-month high of $29.25.

Sienna Biopharmaceuticals (NASDAQ:SNNA) last posted its quarterly earnings data on Thursday, November 9th. The company reported ($1.12) earnings per share for the quarter. equities analysts forecast that Sienna Biopharmaceuticals will post -2.3 EPS for the current year.

Institutional investors and hedge funds have recently modified their holdings of the company. Victory Capital Management Inc. bought a new stake in shares of Sienna Biopharmaceuticals in the 3rd quarter worth approximately $10,198,000. Citadel Advisors LLC bought a new stake in shares of Sienna Biopharmaceuticals in the 3rd quarter worth approximately $440,000. TimesSquare Capital Management LLC bought a new stake in shares of Sienna Biopharmaceuticals in the 3rd quarter worth approximately $8,571,000. Alyeska Investment Group L.P. bought a new stake in shares of Sienna Biopharmaceuticals in the 3rd quarter worth approximately $1,133,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Sienna Biopharmaceuticals in the 3rd quarter worth approximately $274,000. 39.29% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: This piece of content was originally published by Week Herald and is the property of of Week Herald. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://weekherald.com/2018/01/16/sienna-biopharmaceuticals-incs-snna-lock-up-period-to-end-on-january-23rd.html.

Sienna Biopharmaceuticals Company Profile

Sienna Biopharmaceuticals, Inc is a United States-based medical dermatology and aesthetics company. The Company focuses on developing targeted therapies to treat inflammatory skin conditions and aesthetic concerns that impact the health and appearance of patients. Its research and clinical-stage candidates include programs, such as SNA-001, SNA-120 and SNA-125.

Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply